clinical trial · NCT06481306
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Bristol-Myers Squibb·phase2·recruiting·n = 224
Anemia, Sickle CellHealthy VolunteersBMS-986470PlaceboFamotidinePantoprazole
brief summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
started
Jul 17, 2024
primary completion
Apr 30, 2028
completion
Oct 28, 2029
last updated
Jul 6, 2026
official title
A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol